Current and emerging therapies for Alzheimer's disease

Haakon B Nygaard1

  • 1Department of Neurology, Yale University School of Medicine, New Haven, Connecticut.

Clinical Therapeutics
|October 22, 2013
PubMed

Insights

Alzheimer's disease (AD) treatments are advancing, with many promising compounds in clinical trials. This review details current pharmacologic therapies and future experimental strategies for AD therapeutics.

Area of Science:

  • Neuroscience
  • Pharmacology
  • Gerontology

Background:

  • Alzheimer's disease (AD) is a progressive neurodegenerative disorder with increasing global prevalence.
  • Current understanding of AD pathogenesis has significantly advanced, driving therapeutic development.
  • No definitive cure for AD exists, necessitating ongoing research into effective treatments.

Purpose of the Study:

  • To review current pharmacologic treatments for Alzheimer's disease.
  • To provide an overview of experimental strategies poised to shape future AD therapeutics.
  • To synthesize recent progress in AD drug development and clinical testing.

Main Methods:

  • Comprehensive literature review of current and emerging Alzheimer's disease pharmacotherapies.
  • Analysis of clinical trial data for promising AD drug candidates.
  • Synthesis of research trends in Alzheimer's disease pathogenesis and therapeutic targets.

Main Results:

  • Detailed discussion of existing pharmacologic treatments for managing AD symptoms.
  • Identification of numerous compounds in various clinical trial phases showing therapeutic potential.
  • Overview of novel experimental strategies targeting AD pathology.

Conclusions:

  • Substantial progress in understanding AD pathogenesis is yielding promising therapeutic avenues.
  • Current treatments offer symptomatic relief, but future strategies aim to modify disease progression.
  • Continued research and clinical investigation are crucial for developing effective Alzheimer's disease therapies.

Related Concept Videos

Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.3K
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.7K
Alzheimer Disease ll: Pathophysiology01:23

Alzheimer Disease ll: Pathophysiology

Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and...
44
Alzheimer Disease l: Introduction01:29

Alzheimer Disease l: Introduction

Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
38